Baseline carotid intima-media thickness is associated with cardiovascular morbidity and mortality in peritoneal dialysis patients.
cardiovascular disease
cardiovascular mortality
carotid intima-media thickness
fibroblast growth factor 23
peritoneal dialysis
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
13
01
2021
received:
11
09
2020
accepted:
26
01
2021
pubmed:
30
1
2021
medline:
5
2
2022
entrez:
29
1
2021
Statut:
ppublish
Résumé
Carotid intima-media thickness (CIMT) is an early marker of atherosclerosis and is increased in peritoneal dialysis (PD) patients. Association of CIMT with cardiovascular disease (CVD) or mortality is less clear. Fibroblast growth factor-23 (FGF-23) is a hormone associated with vascular calcification, atherosclerosis, and mortality in the hemodialysis population. We investigated whether baseline CIMT and FGF-23 are associated with CVD and mortality in PD patients. Fifty-five PD patients were included. CVD was defined as ischemic heart disease, stroke, or peripheral artery disease. Intact FGF-23 was measured in plasma. CIMT was measured by ultrasonography. Twenty-one patients developed CVD and 12 died over 47.1 ± 33.8 months. Patients with CVD were older (55.9 ± 10.5 vs. 42.5 ± 12.9 years, P < .01), had lower albumin (3.8 ± 0.5 vs. 4.2 ± 0.3 g/dL, P < .01) and higher CIMT (0.87 ± 0.22 vs. 0.61 ± 0.11 mm, P < .01). Patients with mortality were also older (53.5 ± 11.5 vs. 45.8 ± 13.8 years, P = .05), had lower albumin (3.7 ± 0.6 vs. 4.1 ± 0.3 g/dL, P < .01), higher CRP (15.0 ± 8.5 vs. 7.6 ± 8.4 mg/L, P < .01) and CIMT (0.9 ± 0.3 vs. 0.6 ± 0.1 mm, P < .01). Albumin and CIMT were associated with CVD and CIMT > 0.75 mm was associated with cardiovascular mortality. FGF-23 did not show any correlations. CIMT at baseline is associated with CVD and mortality in PD patients.
Identifiants
pubmed: 33511768
doi: 10.1111/1744-9987.13629
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
962-969Informations de copyright
© 2021 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep;351(13):1296-305.
Best PJ, Holmes DR Jr. Chronic kidney disease as a cardiovascular risk factor. Am Heart J. 2003 Mar;145(3):383-6.
Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol. 2002 Jul;13(7):1918-27.
Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Luño J. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl. 2005;93:S35-8.
Kraśniak A, Drozdz M, Pasowicz M, Chmiel G, Michałek M, Szumilak D, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007 Feb;22(2):515-21.
Jegatheesan D, Cho Y, Johnson DW. Clinical studies of interventions to mitigate cardiovascular risk in peritoneal dialysis patients. Semin Nephrol. 2018 May;38(3):277-90.
Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007 Jan 30;115(4):459-67.
Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M, et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S76-9.
Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol. 2001 Nov;12(11):2458-64.
Sato M, Ogawa T, Sugimoto H, Otsuka K, Nitta K. Relation of carotid intima-media thickness and silent cerebral infarction to cardiovascular events and all-cause mortality in chronic hemodialysis patients. Intern Med. 2012;51(16):2111-7.
Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener CI. Waist circumference is associated with carotid intima media thickness in peritoneal dialysis patients. Int Urol Nephrol. 2013 Oct;45(5):1437-43.
Büyükbakkal M, Canbakan B, Eser B, Yayar Ö, Ercan Z, Merhametsiz Ö, et al. The relation between apelin levels, echocardiographic findings and carotid intima media thickness in peritoneal dialysis patients. Ren Fail. 2015 Apr;37(3):433-8.
Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl. 2009;114:S34-42.
Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 Aug 7;359(6):584-92.
Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009 Sep;24(9):2792-6.
Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener CI. Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients. Nephron Clin Pract. 2013;124(1-2):89-93.
Nielsen TL, Plesner LL, Warming PE, Mortensen OH, Iversen KK, Heaf JG. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia. 2019 May-Jun;39(3):258-68.
Kim HJ, Park M, Park HC, Jeong JC, Kim DK, Joo KW, et al. Baseline FGF23 is associated with cardiovascular outcome in incident PD patients. Perit Dial Int. 2016 Jan-Feb;36(1):26-32.
Xu L, Hu X, Chen W. Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis. J Nephrol. 2019 Apr;32(2):307-14.
Bakkaloglu SA, Saygili A, Sever L, Noyan A, Akman S, Ekim M, et al. Assessment of cardiovascular risk in paediatric peritoneal dialysis patients: a Turkish pediatric peritoneal dialysis study group (TUPEPD) report. Nephrol Dial Transplant. 2009 Nov;24(11):3525-32.
Caliskan Y, Ozkok A, Akagun T, Alpay N, Guz G, Polat N, et al. Cardiac biomarkers and noninvasive predictors of atherosclerosis in chronic peritoneal dialysis patients. Kidney Blood Press Res. 2012;35(5):340-8.
Tosetto A, Prati P, Baracchini C, Manara R, Rodeghiero F. Age-adjusted reference limits for carotid intima-media thickness as better indicator of vascular risk: population-based estimates from the VITA project. J Thromb Haemost. 2005 Jun;3(6):1224-30.
Breton CV, Wang X, Mack WJ, Berhane K, Lopez M, Islam TS, et al. Carotid artery intima-media thickness in college students: race/ethnicity matters. Atherosclerosis. 2011 Aug;217(2):441-6.
Besir FH, Yazgan S, Celbek G, Aydin M, Yazgan O, Erkan ME, et al. Normal value correlates of carotid intima- media thickness and affecting parameters in healthy adults. Anadolu Kardiyol Derg. 2012;12(5):427-33.
Bouma-de Krijger A, Vervloet MG. Fibroblast growth factor 23: are we ready to use it in clinical practice? J Nephrol. 2020 Jun;33(3):509-27.
Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant. 2010 Sep;25(9):3033-8.
Waziri B, Musenge E, Duarte R, Dickens C, Dix-Peek T, Rekhviashvili V, et al. Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-mineral and bone disorder with all-cause mortality in south African patients on maintenance dialysis: a 3-year prospective cohort study. PLoS One. 2019;14(5):e0216656.
Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone. 2012 Jun;50(6):1266-74.
Liu WH, Zhou QL, Ao X, Yu HL, Peng WS, He N. Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal dialysis patients. J Cardiovasc Med (Hagerstown). 2012 Sep;13(9):565-9.
Sarmento-Dias M, Santos-Araújo C, Poínhos R, Oliveira B, Silva IS, Silva LS, et al. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clin Nephrol. 2016 Mar;85(3):135-41.
Komaba H, Fukagawa M. The role of FGF23 in CKD-with or without Klotho. Nat Rev Nephrol. 2012 Jun 19;8(8):484-90.
Bi S, Liang Y, Cheng L, Wang Y, Wang T, Han Q, et al. Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis. Int Urol Nephrol. 2017 Sep;49(9):1653-9.